BERKELEY, Calif.--(BUSINESS WIRE)--
Aduro BioTech, Inc., a clinical-stage biotechnology company, today
announced that renowned academic leader and industry veteran, Gerald
Chan, DSc has joined its board of directors. Dr. Chan is the co-founder
of Morningside, a private investment group with venture, private equity
and property investments.
In the life science sector, Morningside focuses on start-up
biotechnology companies founded on novel scientific discoveries. Dr.
Chan serves on the boards of Advanced Cell Diagnostics, Oxyrane, Stealth
Peptides, Synchroneuron, Apellis, Nucana, VTI and Matrivax.
“Dr. Chan and Morningside were early supporters of Aduro and
instrumental in funding our success to date,” said Stephen T. Isaacs,
chairman, president and chief executive officer of Aduro. “Gerald is a
highly respected executive, investor and an internationally renowned
scientist. He has provided counsel to Aduro since 2011 and we are
thrilled to have him formalize his advisory role with membership on our
board of directors.”
Dr. Chan is a member of the Global Advisory Council of the International
Society for Stem Cell Research, the Global Advisory Council of Harvard
University, the Dean's Board of Advisors of the Harvard School of Public
Health and the advisory boards of the Cold Spring Harbor Conferences
Asia, the Johns Hopkins Nanjing Center and the Columbia University
Center for Radiological Research. He is a trustee of Fudan University in
Shanghai and chairs the Board of Overseers of Morningside College of the
Chinese University of Hong Kong. He is a member of the Council on
Foreign Relations, New York.
He received his BS and MS degrees in engineering from UCLA, his Master's
degree in medical radiological physics and Doctor of Science degree in
radiation biology from Harvard University. He did his post-doctoral
training at the Dana-Farber Cancer Institute as a fellow of the Leukemia
Society of America. In 2011, the Chinese University of Hong Kong
conferred on him an honorary Doctor of Social Science degree. He was the
commencement speaker of the Harvard School of Public Health in 2012 and
was elected to an honorary fellowship at Wolfson College of Oxford
University in 2013.
Morningside, founded in 1986, is a diversified investment company with
portfolio investments in private equity and technology ventures. The
group invests actively in biotech companies founded on novel science.
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a private, clinical-stage biotechnology company
focused on immunotherapy for cancer. Aduro has ongoing clinical trials
with its LADD platform in pancreatic cancer, mesothelioma and high-grade
glioma and its immunotherapies are in development in non-small cell lung
cancer, ovarian cancer and prostate cancer. The company is also
developing clinical candidates using novel small molecules that activate
the intracellular STING receptor, a central mediator of the innate
immune response. For more information, please visit www.adurobiotech.com.
Aduro BioTech, Inc.
Greg W. Schafer, 510-809-4801
Source: Aduro BioTech, Inc.